Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Medical school, Tongji University, Shanghai, China.
Cancer Sci. 2020 May;111(5):1461-1467. doi: 10.1111/cas.14354. Epub 2020 Apr 3.
Immunotherapy has become a hotspot in cancer therapy in recent years. Several immune checkpoints inhibitors have been used to treat lung cancer. CD137 is a kind of costimulatory molecule that mediates T cell activation, which regulates the activity of immune cells in a variety of physiological and pathological processes. Targeting CD137 or its ligand (CD137L) has been studied, aiming to enhance anticancer immune responses. Accumulating studies show that anti-CD137 mAbs alone or combined with other drugs have bright antitumor prospects. In the following, we reviewed the biology of CD137, the antitumor effects of anti-CD137 Ab monotherapy and the combined therapy in lung cancer.
近年来，免疫疗法已成为癌症治疗的热点。几种免疫检查点抑制剂已被用于治疗肺癌。CD137 是一种共刺激分子，可介导 T 细胞激活，调节多种生理和病理过程中免疫细胞的活性。针对 CD137 或其配体（CD137L）的研究旨在增强抗癌免疫反应。越来越多的研究表明，抗 CD137 mAbs 单独或与其他药物联合具有光明的抗肿瘤前景。在下面，我们综述了 CD137 的生物学特性、抗 CD137Ab 单药治疗和联合治疗肺癌的抗肿瘤作用。
